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  The 1918 inﬂ  uenza A virus caused the most devastating pandemic, killing approximately 50 
million people worldwide. Immunization with 1918-like and classical swine H1N1 virus vaccines 
results in cross-protective antibodies against the 2009 H1N1 pandemic inﬂ  uenza, indicating 
antigenic similarities among these viruses. In this study, we demonstrate that vaccination with 
the 2009 pandemic H1N1 vaccine elicits 1918 virus cross-protective antibodies in mice and 
humans, and that vaccination or passive transfer of human-positive sera reduced morbidity 
and conferred full protection from lethal challenge with the 1918 virus in mice. The spread of 
the 2009 H1N1 inﬂ  uenza virus in the population worldwide, in addition to the large number 
of individuals already vaccinated, suggests that a large proportion of the population now 
have cross-protective antibodies against the 1918 virus, greatly alleviating concerns and fears 
regarding the accidental exposure  /  release of the 1918 virus from the laboratory and the use of 
the virus as a bioterrorist agent.          
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 T
he 1918 infl  uenza A virus genome encompasses a constel-
lation of genes that result in a highly pathogenic and lethal 
virus that is believed to be responsible for the most devastat-
ing pandemic of the twentieth century, resulting in an estimated 50 
million deaths worldwide. Th   e reconstruction and characterization 
of the formerly extinct 1918 virus have greatly enhanced our knowl-
edge of virulence factors and pathogenesis determinants of this 
virus and other pandemic infl  uenza viruses  1  , facilitating the rapid 
assessment of the potential virulence of the 2009 H1N1 pandemic 
virus  2  . Nevertheless, the same study raised some anxieties because 
of its potential for dual use  1,3  , that is, this virus could be used not 
only to understand how to prevent and treat severe infl  uenza 
virus infections but also to construct potential bioterrorist agents. 
Questions were also raised about the possible consequences of an 
unwanted accidental release from the laboratory  3 .  Although  these 
concerns could be addressed by the use of biocontainment facilities 
and the availability of eff  ective antivirals, currently no licensed vac-
cine exists against the 1918 pandemic infl  uenza virus. 
  Inactivated and live attenuated vaccines are the main means of 
protection against infl  uenza viruses in the general human popula-
tion. Th   ere is extensive knowledge on vaccine safety, and vaccines 
are widely used every year to immunize against seasonal infl  uenza 
strains. Th  e emergence of the 2009 H1N1 pandemic infl  uenza A 
virus and the potential devastating consequences of a more virulent 
second wave prompted governments to work together with vac-
cine manufacturers to rapidly develop a pandemic strain vaccine 
that has now become available worldwide. It is estimated that mil-
lions of individuals have now been vaccinated with this novel vac-
cine strain. As a consequence of continued global circulation of the 
new H1N1 virus, and as it remains the predominant circulating 
infl  uenza A strain in the Northern and Southern Hemisphere  4,5 ,  the 
current recommendation from World Health Organization includes 
the pandemic strain as part of the 2010  –  2011 trivalent vaccine 
formulation  5 . 
  Recent studies have demonstrated that 1918-like and classical 
swine H1N1 viruses share antigenic similarities  6 – 9 .  Unexpectedly, 
the 1918 and 2009 H1N1 haemagglutinin (HA) proteins were found 
to have the highest homology in the known antigenic sites. In this 
paper, we demonstrate that immunization of mice and humans 
with the novel 2009 H1N1 vaccine strain results in the production 
of antibodies that crossreact with the 1918 virus, and that these 
antibodies are capable of conferring full protection in mice from a 
1918 lethal challenge. Passive transfer of human 2009 H1N1-positive 
sera or mouse 2009 H1N1 HA-specifi   c monoclonal antibodies 
(mAbs) was suffi   cient to protect mice from the lethality of 1918 virus 
infection. Our data indicate that vaccination or previous exposure 
to the 2009 H1N1 pandemic virus elicits cross-protective antibod-
ies in the general human population, and that antigenic site Sa is an 
important cross-protective epitope between these two viruses. More 
important, our results should ease concerns of accidental release of 
the 1918 virus from the laboratory, or its use as a bioterrorist agent, 
as a cross-protective vaccine is now available and a large proportion 
of the general population would already have crossreactive anti-
bodies. Th   is vaccine should also serve as an additional layer of safety 
for researchers working with the 1918 infl  uenza virus.   
 Results  
  2009 H1N1 vaccine protects mice from a lethal 1918 virus 
challenge      .     It was recently found that the 2009 H1N1 pandemic 
virus shows antigenic similarities to 1918-like and classical swine 
H1N1 viruses  6 – 9  . Here, we evaluated whether immunization of 
mice with the 2009 H1N1-inactivated vaccine would elicit cross-
protective antibodies capable of conferring protection against 
the more lethal 1918 pandemic infl  uenza virus. At 21 days aft  er 
vaccination, animals that contained haemagglutination inhibition 
(HI) titres of                 40 against homologous virus were selected and 
matched for challenge experiments.   C57B / 6   mice immunized with 
an inactivated 6:2 vaccine engineered with the six internal genes of 
A / Puerto  Rico / 8 / 34  and  that  contained  the  HA  and  neuraminidase 
(NA)  genes  of  the  pandemic  H1N1  A / California / 04 / 2009  (Cal / 09) 
strain that had post-vaccination HI titres of 160 – 1280 were protected 
from death and exhibited limited morbidity (reduced weight loss) 
aft  er a 1918 virus lethal challenge with 300 times the 50  %   lethal 
dose (300 LD  50 ;  7.35 × 10 4   plaque-forming units (p.f.u.);   Fig. 1a,b  ). 
Th  is protection was similar to that observed in mice vaccinated 
with homologous virus-like particles (VLPs) containing the 1918 
HA  (A / South  Carolina / 1 / 18)  and  NA  (A / Brevig  Mission / 1 / 18) 
that exhibited post-vaccination HI titres of 40  –  640, and contrasted 
sharply with the level of morbidity and  /  or mortality observed when 
a contemporary seasonal H1N1 (A / Brisbane / 59 / 2007 (Bris / 59 / 07))- 
or H3N2 (A / Brisbane / 10 / 2007 (Bris / 10 / 07))-inactivated vaccine was 
administered (both eliciting post-vaccination HI titres of 80  –  640 
      Figure  1     |          An  inactivated  2009  H1N1  vaccine  elicits  cross-protective  antibodies  against  the  1918  pandemic  H1N1 virus in mice. (  a – c )   C57B / 6   mice 
(5 weeks old) were immunized twice intramuscularly (at 28 and 14 days before lethal challenge with 300 LD  50   of 1918 inﬂ  uenza virus on day 0) with 15       μ g 
of the indicated inactivated virus or with 1918 VLP. The mock-infected group received PBS instead of virus challenge. Mice were 9 weeks old at the time 
of challenge. (  a  ) Body weights represent the average of   n         =       5 mice per immunization strategy and error bars represent s.d. of mice remaining at each time 
point. Asterisks below data points represent statistical signiﬁ  cant differences in weights, determined by an unpaired Student  ’  s   t -test  ( P     <    0.05),  for  the  no 
vaccine, Bris  /  59  /  07 (H1N1) and Bris  /  10  /  07 (H3N2) vaccination groups for days 3  –  8 (when more than three mice were remaining in each group); and 
for Cal  /  04 at the indicated time points, as compared with the mock group. (  b  ) Percentage survival was calculated from the groups above (  n     =    5  mice  per 
group). The log-rank test was used to determine signiﬁ   cance  ( *  P     <    0.05).  ( c  ) Viral titres in lungs of vaccinated mice on days 2 (squares) and 4 (circles) 
after challenge. Titres are shown for two (black arrows) or three mice per group at each time point. Black bars represent the average values, and statistical 
signiﬁ  cance using an unpaired two-tailed Student  ’  s   t -test  ( *  P     <    0.05)  was  determined  as  compared  with  the   ‘ no  vaccine ’   control  groups.  ARTICLE   
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and  40 – 160,  respectively;   Fig.  1a,b ).  Th  is diff  erence in morbidity 
between the Cal  /  09 and Bris  /  59  /  07 vaccine groups was not due to 
slight diff  erences in HI titres, as, when animals containing the same 
level of neutralizing antibodies from both groups were compared 
individually, the magnitude of the weight loss was consistently 
higher in Bris  /  59  /  07 immunized mice (  Fig. 1a  ). In addition, Cal  /  09- 
and 1918-vaccinated animals had lower virus titres in their lungs 
compared with seasonal vaccine controls (  Fig. 1c  ), indicating an 
equivalent protective effi   cacy of the Cal  /  09 vaccine in mice.     
  2009 H1N1 human-positive sera protect against the 1918 virus   .  
    We next evaluated whether vaccination with a 2009 H1N1 licensed 
inactivated vaccine, used in the 2009  /  2010 Northern Hemisphere 
winter season, elicited 1918 crossreactive antibodies in humans. 
We found that volunteers, 19  –  82 years of age, who mounted a 
medium to robust antibody response aft  er a single dose of 2009 H1N1 
vaccine (HI titres of            40),  also  displayed  signifi  cant 1918 infl  uenza 
HI titres (           20,   Table  1 ).  Th   is response is specifi  c, as volunteers that 
received only seasonal trivalent inactivated vaccine containing H1N1 
(Bris / 59),  H3N2  (Bris / 10)  and  infl   uenza  B  (B / Brisbane / 60 / 2008) 
viruses did not have        >       40 HI titres against Cal  /  09 or 1918 (  Table 1  ). 
We tested whether these positive polyclonal human antibodies were 
capable of protecting mice against a lethal 1918 virus challenge. 
Mice passively immunized with undiluted human post-vaccination 
sera  (100    μ  l) had HI titres of 20  –  80 against the 1918 virus (  Table 2  ) 
at the time of infection and were fully protected from a 50 LD  50  
(1.19 × 10 4       p.f.u.) 1918 virus challenge (  Fig. 2a,b  ). In contrast, mice 
administered pre-vaccination sera or that received no treatment 
as control (no sera) all succumbed to infection by day 10. Further-
more, mice treated with post-vaccination human sera demonstrated 
a 32- to 141-fold reduction in viral burden in the lungs as compared 
with controls on day 2 (  Fig. 2c  ). At day 4 aft  er challenge, some mice 
showed an increased viral titre in the lungs as compared with day 2, 
possibly because of waning antibody levels. However, these mice 
did not exhibit overt signs of disease, as evidenced by weight loss, 
lethargy and diffi   culty in breathing or mortality. In addition, we 
evaluated whether neutralizing mAbs raised against Cal  /  09 HA, 
which map to antigenic site Sa  6   (see Methods), were suffi   cient to 
protect mice against a lethal challenge with the 1918 virus. Admin-
istration of two neutralizing mouse anti-Cal / 09 HA mAbs protected 
mice from morbidity and mortality against lethal challenge at levels 
equivalent to administration of a neutralizing mAb raised against 
the 1918 HA (  Fig. 3a,b  ). Virus was undetectable in the mice pas-
sively immunized with either 1918- or Cal  /  09-neutralizing mAbs 
at both time points analysed (  Fig. 3c  ). Overall, these data indicate 
that the 2009 H1N1 licensed vaccine elicits neutralizing antibodies 
suffi   cient to confer full cross-protection to a lethal 1918 pandemic 
infl   uenza  virus  challenge.    
 Discussion 
  Initial concerns about the safety of working with the highly patho-
genic 1918 virus called for the development of a vaccine  10 .  Th  e  data 
    Table 2           |       Cal  /  09 and 1918 HI titres of mice sera 24     h after passive immunization with pre- and post-vaccination human sera. 
    Human  sera  from  Table  1      *         Age  of  donor     Cal / 09      † , ‡          1918      † , ‡      
          Pre     Post     Pre     Post  
    2       §         2 1        <     1 0     20 – 40        <     1 0     20 – 40  
    4                3 4        <     1 0     80        <     1 0     80  
    6     §       4 2        <     1 0     20 – 40        <     1 0     20 – 40  
    7      §       4 3        <     1 0     40        <     1 0     40  
    PBS    NA   NA       <    10   NA       <    10 
     NA,  not  applicable.   
    *      Mice  passively  immunized  with  100    μ  l of pre- and post-vaccination sera from individuals immunized with the 2009 H1N1-inactivated vaccine as shown in Table 1.     
    †          The 6:2 Cal  /  09 vaccine virus or 1918 VLPs were used for HI assays.     
    ‡     Bold  fonts  highlight  crossreactive-positive  sera.   
    §          Human serum samples obtained on days 0 (pre) and 21 (post) after vaccination, respectively.     
               Human serum samples obtained on days 0 (pre) and 63 (post) after vaccination, respectively.     
      Table 1           |       HI titres of pre- and post-vaccination human sera against Cal  /  09 (homologous) and 1918 (heterologous) HA. 
    Sample     Age  of  donor     Cal / 09      * , †         1918      * , †         Vaccinated  with  
          Pre     Post     Pre     Post     2009  H1N1     Seasonal  TIV  
    1       ‡         1 9        <     1 0     80    10    20     Yes    Yes 
    2      ‡       2 1        <     1 0     1280        <     1 0     1280     Yes    Yes 
    3       §         3 3        <     1 0     80    20    40     Yes    No 
    4      §       3 4        <     1 0     2560        <     1 0     2560     Yes    Yes 
    5      §       3 4        <     1 0     80        <     1 0     80     Yes    Yes 
    6      ‡       42   10    320        <     1 0     320     Yes    Yes 
    7      ‡       4 3        <     1 0     320    20    640     Yes    Yes 
    8      ‡       4 9        <     1 0     40        <     1 0     20     Yes    Yes 
    9      §       55   10    1280        <     1 0     1280     Yes    Yes 
    10      §       6 0        <     1 0     1280    10    1280     Yes    Yes 
    11      §       67   10    640        <     1 0     1280     Yes    Yes 
    12      §       67   10    640    80    640     Yes    Yes 
    13      §       8 2        <     1 0     2560        <     1 0     640     Yes    No 
    14      §       51       <    10       <    10       <    10       <    10   No   Yes 
    15      §       74       <    10   10   10   40   No   Yes 
    *          The 6:2 Cal  /  09 vaccine virus or 1918 VLPs were used for HI assays.     
    †      Bold  fonts  highlight  crossreactive-positive  sera.   
    ‡          Human serum samples obtained on days 0 (pre) and 21 (post) after vaccination, respectively.     
    §          Human serum samples obtained on days 0 (pre) and 63 (post) after vaccination, respectively.     ARTICLE
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presented in this study indicate that immunization of humans with 
the 2009 H1N1-inactivated vaccine or natural infection with the 
2009 H1N1 virus will confer protective antibody responses against 
the 1918 pandemic infl   uenza virus in the general population. 
In addition, although substantial morbidity (body weight loss) was 
observed in mice immunized with the seasonal H1N1 (Bris  /  59), 
this vaccine off  ered partial protection from death aft  er a 1918 lethal 
challenge, a phenomenon that has been previously described for 
hetero  logous (antigenically diff  erent) H1N1 virus strains  6,11 .  Th  e 
under  lying mechanism responsible for this partial protection 
is unclear and is thought to be mainly due to anti-HA immune 
responses  11  , although the activity of antibodies against other viral 
proteins cannot be ruled out. Nevertheless, this partial cross-
protection provides additional indirect evidence that humans 
vaccinated against or exposed to previous seasonal H1N1 strains 
might have variable levels of cross-protective immunity against the 
1918 virus. Our studies with mAbs further demonstrate that site Sa is 
an important cross-protective epitope, and thus provide a mechanistic 
explanation to the high level of cross-protection seen in this study 
and previously among the 1918 and the Cal  /  09 vaccines  6 . 
  Our results obtained with the mouse model pave the way 
for further evaluation of the effi   cacy of the 2009 H1N1 pandemic 
vaccine strain in its ability to protect against 1918 virus. Th  us, it 
will be valuable to establish the level of protection that this vaccine 
would elicit in other animal models, particularly in guinea-pigs, 
ferrets and monkeys, which will be helpful in assessing morbidity, 
shedding and in establishing whether vaccination can prevent 
contact and  /  or aerosol transmission of the virus. 
 It is important to note that the spread of the 2009 H1N1 infl  uenza 
virus in the population worldwide, in addition to the large number 
of individuals already vaccinated, suggests that a large proportion 
of the population now have cross-protective antibodies against the 
1918 virus, considerably reducing the concerns of the consequences 
of an unwanted or malicious release of this lethal strain of infl  u-
enza virus. In addition, the wide availability of the 2009 H1N1 virus 
vaccine should greatly alleviate some of the biosafety and biosecu-
rity concerns voiced at the time of the reconstruction of the 1918 
virus. Moreover, our data will likely aff  ect the development of future 
biosafety measures and policies for working with the 1918 infl  u-
enza A virus, as immunization with the current 2009 H1N1 vaccine 
      Figure 2       |                 Passive immunization with post-vaccination 2009 H1N1 human-positive sera protects mice from 1918 virus lethality. (  a – c )  9-week-old 
mice were treated with a single dose of 100       μ  l of the indicated human sera or PBS (no sera) intraperitoneally 24     h before challenge with 50 LD  50   of 1918 
virus. (  a  ) Average body weights of   n         =       4  –  5 mice per group (black arrow denotes group with four animals), with error bars representing the s.d. for mice 
remaining at each time. Time points in which the body weight of all the human pre-vaccination groups is signiﬁ  cantly different from their respective 
human post-vaccination group are shown (  *    P     <    0.05),  as  determined  by  an  unpaired  two-tailed  Student ’ s   t -test.  ( b  ) Survival curves are shown for the mice 
groups in (  a  ). The log-rank test was used to evaluate signiﬁ   cance  ( *  P         <       0.05) for survival outcome, black arrow indicates group with four animals. (  c )  Lung 
viral titres in passively immunized mice on days 2 (squares) and 4 (circles) after challenge. Viral titres of two (shown with black arrow) or three mice per 
group per time point are shown as in   Figure 1  . Signiﬁ  cantly different data points (  *    P     <    0.05)  between  the  corresponding  pre-  and  post-sera  immunizations 
are shown for each group, as determined by an unpaired two-tailed Student  ’  s   t -test.  
   Figure  3     |          Passive  immunization  with  Cal / 09-HA  speciﬁ  c antibodies and 2009 H1N1 human-positive sera protects mice from 1918 virus lethality. 
(  a – c  ) mice (9 weeks old) were treated with a single dose of either 150       μ  g of each mAb (150       μ l  ﬁ  nal volume) or 100       μ  l of human sera intraperitoneally 
24     h before challenge with 50 LD  50   of 1918 virus, or mock challenged with PBS (mock group). (  a  ) Body weights represent the average from   n     =    5  mice 
per immunization strategy and error bars represent s.d. of mice remaining at each time point. Statistical signiﬁ   cance  ( *  P     <    0.05)  was  determined  by  an 
unpaired two-tailed Student  ’  s   t  -test for the control mAb group as compared with the mAb treatment groups, and for the human pre-sera as compared 
with the human post-sera treatment group. (  b  ) Percentage survival of   n     =    5  mice  per  group.  Statistical  differences  ( *  P     <    0.05)  are  shown  as  compared 
as above and were determined by the log-rank test. (  c  ) Lung viral titres of passively immunized mice on days 2 (squares) and 4 (circles) after challenge. 
Viral titres for   n         =       3 mice per group per time point are shown with their respective average represented as black bars. Signiﬁ  cant differences (  *    P     <    0.05) 
in viral titres were determined by an unpaired two-tailed Student  ’  s   t -test.  ARTICLE   
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should provide an additional layer of safety for scientists conducting 
research with this virus.     
 Methods  
  Cell lines and virus strains   .    Human  embryonic  kidney  (293T)  cells  were  main-
tained in Dulbecco  ’  s modifi  ed Eagle  ’  s medium supplemented with 10  %   fetal bovine 
serum  (FBS)  and  1000   U   ml     −     1   of  penicillin / streptomycin.  Madin – Darby  canine  kid-
ney (MDCK) cells were maintained in minimum essential medium supplemented 
with 10  %   FBS and penicillin  /  streptomycin.   Cell culture reagents   were from   Gibco 
Life Technologies  . Th   e H1N1 viruses used in this study are as follows: the recom-
binant 1918 virus (1918) bearing the HA from A  /  South Carolina  /  1  /  18 and the 
other  seven  genes  from  A / Brevig  Mission / 1 / 18,  A / Puerto  Rico / 8 / 34-MSSM  (PR8), 
Bris / 59 / 07  and  Cal / 09.  Th   e Bris  /  10  /  07 virus strain was used as an H3N2 control. 
Experiments involving 2009 H1N1 and 1918 pandemic viruses were conducted 
under Biosafety level 3-enhanced conditions in accordance with guidelines of the 
United States Centers for Disease Control and Prevention. Th   e 1918 virus stocks 
were grown in MDCK cells. All other viruses were grown in 10-day-old 
eggs  at  37 ° C  for  2 – 3  days.   
  Vaccine preparation   .    We  generated  a  recombinant  infl  uenza A virus carrying 
HA  /  NA from Cal  /  09 and the internal six genes from PR8 (referred to as Cal  /  09 
6:2 in the reminder of the paper)  12  , by transfecting 293T cells with eight ambisense 
pDZ vectors encoding the eight viral genes and proteins. At 24     h aft  er transfection, 
the supernatant was collected and inoculated into 8-day-old embryonated 
chicken eggs. Aft  er 3 days of incubation at 35   °  C, the allantoic fl  uid containing 
the rescued virus was plaque purifi  ed in MDCK cells. For virus vaccines, viruses 
were grown once in 10-day-old embryonated chicken eggs at 37   °  C for 2 days  6 . 
Th   e allantoic fl  uid was clarifi  ed by low-speed centrifugation at 2,000       g   for 10     min at 
4   °  C. Viruses were pelleted on a 30  %   sucrose cushion by centrifugation at 85,000       g  
in a   SW28 rotor   (  Beckman Coulter  ) for 2     h at 4    °  C. Viral pellets were resuspended 
in calcium borate buff   er  pH    =    7.0  (143   mM  sodium  chloride,  10   mM  calcium  chlo-
ride, 20     mM boric acid and 2.5     mM sodium borate) at a concentration of 1     mg     ml      −     1 . 
Th   e viruses were inactivated by formaldehyde (0.9  %   fi  nal concentration). Th  e  1918 
virus-based vaccine consisted of VLPs obtained by co-transfection of HA (A  /  South 
Carolina / 1 / 18)  and  NA  (A / Brevig  Mission / 1 / 18)  into  293T  cells 13 .  Th  e  released 
VLPs were collected and purifi  ed from the culture supernatant on a 30  %   sucrose 
cushion by centrifugation for 2     h at 85,000       g   in an SW28 rotor. Immunization doses 
were based on the amount of total protein concentration measured by the Bradford 
method, and seroconversion was assessed on day 21 aft   er  vaccination.   
  Site Sa HA-speciﬁ  c mouse mAbs   .     Th  e  HA-specifi  c mouse mAbs 29E3 and 39E4 
against the pandemic H1N1 2009 and 1918 viruses, respectively, are described 
in Manicassamy   et al  6 .  Th   e mAb 31C2 against 2009 H1N1 HA was generated by 
the hybridoma shared research facility at Mount Sinai School of Medicine, New 
York. We infected 6-week-old BALB  /  C mice intranasally with 5  ×  10  4    p . f . u .   o f  
infl  uenza virus Cal  /  09. To boost Cal  /  09 HA-specifi  c B cells, mice were given an 
intravenous dose (2  ×  10  7       p.f.u.) of Cal  /  09 6:2 virus 4 weeks later. On day 3 aft  er the 
boost, spleens were collected and B cells were fused with SP2  /  0 myeloma cells by 
addition of polyethylene glycol. Supernatants from the resulting hybridomas were 
screened by immunofl  uorescence staining of 293T cells transfected with the HA 
expression plasmid, pDZ-HA (Cal  /  09). Positive hybridomas were subcloned and 
re-screened. Th   e antibody was isotyped as IgG2b using the   IsoStrip kit   (  Roche  ) 
and purifi  ed using a Protein A sepharose column. Cal  /  09 escape mutant viruses 
containing a G172E mutation (H3 numbering       =       G158E) in the HA protein were 
generated by incubating Cal  /  09 virus with excess 31C2 antibody for 1     h at room 
temperature (RT). Th   e mixture was inoculated into 10-day-old embryonated eggs 
and incubated at 37  °  C for 48     h. Viruses that displayed loss of HI activity against 
this mAb were amplifi  ed and sequenced directly from the reverse   transcription  –
 PCR  product.   
  Ethics statement and human specimens   .    All  research  studies  involving  the  use 
of human specimens were reviewed and approved by the Institutional Review 
Boards of Saint Louis University School of Medicine and of Mount Sinai School 
of Medicine. Pre- and post-vaccination human sera samples were obtained from 
subjects who were 18 years of age or older, who were enrolled in clinical trials to 
test the safety and immunogenicity of an inactivated 2009 H1N1 infl  uenza vaccine 
at the National Institute of Allergy and Infectious Disease Vaccine and Treatment 
Evaluation Unit at Saint Louis University. Experiments to test the reactivity of these 
sera against the 1918 and Cal  /  09 HAs were conducted blind.     
  HI assay      .     Mouse and human sera were inactivated using a trypsin-heat-periodate 
treatment  6,14  . We mixed one volume of sera with half a volume of   trypsin   8     mg     ml      −     1  
(  Sigma-Aldrich  ) in 0.1     M phosphate buff  er, pH 8.2, and incubated the samples 
for  30   min  at  56  ° C.  Th   e samples were cooled to RT, mixed with three volumes of 
0.11     M metapotassium periodate and incubated for 15     min at RT. Th   e samples were 
then mixed with three volumes of 1  %   glycerol saline and further incubated for 
15     min at RT. A fi  nal 2.5 volumes of 85  %   saline were added to dilute the samples 
to a concentration of 1:10. HI assays of mAbs and sera were conducted following 
standard protocols  13 .  Briefl  y, two-fold serial dilutions of mouse, human sera or 
mAbs were mixed and pre-incubated in 96-well plates for 30     min at 4   °  C with 8 HA 
units of virus per well. Turkey red blood cells were added at a fi  nal concentration of 
0.25  %  , and the plate was incubated at 4   °  C for 30     min. HI titres were determined as 
the highest dilution that displayed haemagglutinating activity. Specifi  c HI activity 
of mAbs was calculated as the lowest concentration of mAb that displayed haemag-
glutinating  activity.   
  Mouse experiments   .       C57BL / 6   female mice   (  Jackson Laboratories  ) were 
anaesthetized with ketamine  –  xylaxine intraperitoneally and intranasally infected 
with the indicated dose of virus diluted in 50       μ  l of PBS. All animal procedures 
performed in this study are in accordance with Institutional Animal Care and Use 
Committee (IACUC) guidelines, and have been approved by the IACUC of Mount 
Sinai School of Medicine. Mice showing            25 %   of  body  weight  loss  were  consid-
ered to have reached the experimental end point and were humanely euthanized. 
To obtain viral lung titres, lungs of infected mice were excised on days 2 and 4 
aft  er infection and homogenized using a   mechanical homogenize  r (  MP Biochemi-
cals  ). Virus in homogenates was quantifi  ed by plaque assay on MDCK cells. For 
immunization studies, 5-week-old female   C57BL / 6   mice were administered 15       μ g 
of inactivated virus or 1918 VLP by intramuscular injection in the hind leg. Two 
weeks later, a second dose of the same amount of inactivated virus was given as 
a boost. Four weeks aft  er initial vaccination, the mice were challenged with 300 
LD  50   of the 1918 virus. 
  For passive immunizations, 9-week-old   C57BL / 6   female mice were adminis-
tered (intraperitoneally) 100       μ  l of undiluted pre- and post-vaccination human sera, 
from volunteers immunized with the pandemic 2009 H1N1-inactivated vaccine 
(Table 1) or 150       μ  g of the indicated mAb, 24     h before lethal challenge with 50 LD  50  
of the 1918 virus. Survival and body weight loss were monitored for 14 days aft  er 
challenge, and lung viral titres were obtained on days 2 and 4 aft  er challenge. All 
mice were 9  –  10 weeks old at the time of lethal challenge.     
  Statistical analysis   .    Statistical  signifi  cance (  P     <    0.05)  was  determined  using  a 
two-tailed  unpaired  Student ’ s   t  -test for body weight changes and lung viral titres 
as described in each fi  gure. A log-rank test was used to establish signifi  cant diff  er-
ences (  P     <    0.05)  for  survival  curves.                 
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